Clinical Data

Summit shares descend as PD-1/VEGF asset misses early survival mark

BioSpace

Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement--but the early analysis delivered disappointment for t

Oncology

Read full story

pharminent May 4, 2026 (Last updated: May 4, 2026)

BioSpace

Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement–but the early analysis delivered disappointment for t

Oncology

Read full story

Related Stories

BMS brings the buzz around late-stage readouts amid a so-so Q1

GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints

Survodutide delivers 16.6% weight loss in major phase 3 obesity trial

You May Have Missed

Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq

223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease

Eli Lilly to Acquire Kelonia Therapeutics

Gene therapy’s evidence problem–lessons from recent FDA decisions